Subscribe to RSS
DOI: 10.1055/s-0029-1234086
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
The Use of Thyrogen® in the Treatment of Differentiated Thyroid Carcinoma: An Intraindividual Comparison of Clinical Effects and Implications of Daily Life
Publication History
received 24.02.2009
first decision 12.05.2009
accepted 26.06.2009
Publication Date:
23 October 2009 (online)
![](https://www.thieme-connect.de/media/eced/201008/lookinside/thumbnails/10.1055-s-0029-1234086-1.jpg)
Abstract
Aim: Withdrawal of levothyroxine with resultant hypothyroidism is still used in preparation for I-131 diagnostic whole-body scan (DWBS) and thyroglobulin (TG)-measurement in patients afflicted with differentiated thyroid cancer (DTC). Recombinant human thyroid-stimulating hormone (rhTSH) enhances TSH stimulation obviating the clinical and economical consequences of hypothyroidism. Primary aim of this study was an intraindividual comparison of diagnostic follow-up measurements under these two sets of conditions by taking clinical and socio-economic parameters into account. Second aim was to determine a clear patient preference for the one method or the other.
Methods: This non-interventional observational study included patients (n=192 signed informed consent, n=128 protocol compliant patients without need for therapeutic intervention) with DTC first treated by thyroidectomy and radioiodine ablation. Control visits including I-131 DWBS were planned at 3–6 months post-thyroidectomy after a phase (KU 1) of thyroid hormone withdrawal (THW) and again after 6–12 months later in a euthyroid state under exogenous stimulation with rhTSH (KU 2). Study design was open, prospective and multicentric. Data collected consisted of patient information (SF-12® Health Survey), thyroid-specific results of clinical examinations and several aspects of daily life, e. g., employment, days of absence from work and other economic aspects.
Results: In contrast to KU 1, in KU 2 there is a highly significant improvement (p<0.0001) in all studied clinical symptoms and aspects of managing daily life. A significant increase of the SF-12® health survey score could also be identified. Mental score showed a higher increase than physical score. Included patients were less absent from work before KU 2, (absent 4.5%, median 4 days in euthyroid state [range 2–5 d]), vs. before KU 1 (absent 47.8%, median 10 days in hypothyroid state [range 1–30 d]). After KU 2 7.7% of the euthyroid patients was absent from work (median 5 days) while 37.5% was after KU 1 (median 6 days).
Conclusion: Included patients benefited subjectively and objectively from the use of rhTSH for diagnostic procedures in the treatment of DTC. A clear preference (127 of 128) of analyzed patients could be identified for exogenous stimulation with rhTSH.
Key words
rhTSH - thyroid cancer - hypothyroidism - diagnostic whole body
References
- 1 Billewicz WZ, Chapman RS, Crooks J. et al . Statistical methods applied to the diagnosis of hypothyroidism. Q J Med. 1969; 38 ((150)) 255-266
- 2 Borget I, Corone C, Nocaudie M. et al . Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with thyrogen and thyroid hormone withdrawal. Eur J Endocrin. 2007; 156 ((5)) 531-538
- 3 Borget I, Remy H, Chevalier J. et al . Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging. 2008; 35 ((8)) 1457-1463
- 4 Botella-Carretero JI, Gomez-Bueno M, Barrios V. et al . Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocrine-Related Cancer. 2004; 11 ((2)) 345-356
- 5 Cohen O, Dabhi S, Karasik A. et al . Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH. Eur J Endocrin. 2004; 150 ((3)) 285-290
- 6 Constant EL, de Volder AG, Ivanoiu A. et al . Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. J Clin Endocrinol Metabol. 2001; 86 ((8)) 3864-3870
- 7 Dietlein M, Dressler J, Eschner W. et al . Procedure guideline for I-131 whole-body scintigraphy for differentiated thyroid cancer (version 2). Nuklearmedizin. 2003; 42 ((3)) 123-125
- 8 Dietlein M, Dressler J, Eschner W. et al . Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3). Nuklearmedizin. 2007; 46 ((5)) 206-212
- 9 Dietlein M, Dressler J, Escher W. et al . Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). [German]. Nuklearmedizin. 2007; 46 ((5)) 213-219
- 10 Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997; 7 ((4)) 613-619
- 11 Duntas LH, Biondi B. Short-term hypothyroidism after levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur J Endocrinol. 2007; 156 ((1)) 13-19
- 12 Franchini M. Hemostatic changes in thyroid diseases. Hematology. 2006; 11 ((3)) 203-208
- 13 Gandek B, Sinclair SJ, Kosinski M. et al . Psychometric evaluation of the SF-36 health survey in Medicare managed care. Health Care Financ Rev. 1998; 25 ((4)) 5-25
- 14 Goldberg P. Life-threatening hypothyroidism during thyroid hormone withdrawal for routine thyroid cancer surveillance. Endocrinologist. 2007; 17 ((2)) 116-118
- 15 Haugen BR, Cooper DS, Emerson CH. et al . Expanding indications for recombinant human TSH in thyroid cancer. Thyroid. 2008; 18 ((7)) 687-694
- 16 den Hollander JG, Wulkan RW, Mantel MJ. et al . Correlation between severity of thyroid dysfunction and renal function. Clin Endocrinol. 2005; 62 ((4)) 423-427
- 17 Leboeuf R, Perron P, Carpentier AC. et al . L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial. Clin Endocrinol (Oxf). 2007; 67 ((6)) 839-844
- 18 Lien EA, Nedrebo BG, Varhaug JE. et al . Plasma total homocysteine levels during short-term iatrogenic hypothyroidism. J Clin Endocrinol Metabol. 2000; 85 ((3)) 1049-1053
- 19 Luster M. Present status of the use of recombinant human TSH in thyroid cancer management. Acta Oncol. 2006; 45 ((8)) 1018-1030
- 20 Luster M, Felbinger R, Dietlein M. et al . Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid. 2005; 15 ((10)) 1147-1155
- 21 Mernagh P, Campbell S, Dietlein M. et al . Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol. 2006; 155 ((3)) 405-414
- 22 Münte TF, Lill C, Otting G. et al . Cognitive changes in short-term hypothyroidism assessed with event-related brain potentials. Psychoneuroendocrinology. 2004; 29 ((9)) 1109-1118
- 23 Nagamachi S, Jinnouchi S, Nishii R. et al . Cerebral blood flow abnormalities induced by transient hypothyroidism after thyroidectomy – Analysis by Tc-99 m-HMPAO and SPM96. Ann Nucl Med. 2004; 18 ((6)) 469-477
- 24 Nijhuis TF, van Weperen W, de Klerk JMH. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschr Nucl Geneeskd. 1999; 21 98-100
- 25 Reiners C, Dietlein M, Luster M. Radio-iodine therapy in differentiated thyroid cancer: indications and procedure. Best Pract Res Clin Endocrinol Metab.. 2008; 22 ((6)) 989-1007 . Review
- 26 Rosenthal MS. The impaired hypothyroid patient: ethical considerations and obligations. Thyroid. 2007; 17 ((12)) 1261-1267
- 27 Schroeder PR, Haugen BR, Pacini F. et al . A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006; 91 ((3)) 878-884
- 28 Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34 ((3)) 220-233
- 29 Woolam GL. Cancer statistics, 2000: a benchmark for the new century. CA Cancer J Clin. 2000; 50 ((1)) 6
Correspondence
Dr. C. Dueren
Department of Nuclear Medicine
University of Wuerzburg
Josef-Schneider-Straße 2
97080 Wuerzburg
Germany
Phone: +49/9312/013 58 68
Fax: +49/9312/013 59 70
Email: dueren_c@klinik.uni-wuerzburg.de